K36

Huawei Interprets the F5.5G All-Optical Target Network to Accelerate Gigabit Popularization and Promote 10Gbps Commercial Use

Retrieved on: 
Monday, February 26, 2024
Metro, GPON, Architecture, ODN, MWC, Backbone, TB, FTTR, Cos, OTN, FTTH, Huawei, K36, ASON, E2E, OSN, Data-rate units, Internet service provider

The participants advocated seizing the development opportunities of the gigabit broadband market and ushering in the 10Gbps network era.

Key Points: 
  • The participants advocated seizing the development opportunities of the gigabit broadband market and ushering in the 10Gbps network era.
  • Kim Jin, Vice President of Huawei Optical Business Product Line, interprets the F5.5G all-optical target network to accelerate gigabit popularization and support the evolution of future networks to 10Gbps, opening up the new era of F5.5G commercial use.
  • Under this trend, Huawei proposes an F5.5G all-optical target network need to build an F5.5G all-optical target network that supports 3 network capabilities, and 4 network architecture.
  • Kim Jin said, "Huawei will continue to innovate based on the F5.5G all-optical target network, to help carriers seize development opportunities in the gigabit market and accelerate F5.5G commercial use, embracing the new wave of market prosperity."

Huawei Interprets the F5.5G All-Optical Target Network to Accelerate Gigabit Popularization and Promote 10Gbps Commercial Use

Retrieved on: 
Monday, February 26, 2024
Metro, GPON, Architecture, Multimedia, ODN, MWC, Backbone, TB, FTTR, Cos, OTN, FTTH, Huawei, K36, ASON, E2E, OSN, Data-rate units

The participants advocated seizing the development opportunities of the gigabit broadband market and ushering in the 10Gbps network era.

Key Points: 
  • The participants advocated seizing the development opportunities of the gigabit broadband market and ushering in the 10Gbps network era.
  • Kim Jin, Vice President of Huawei Optical Business Product Line, interprets the F5.5G all-optical target network to accelerate gigabit popularization and support the evolution of future networks to 10Gbps, opening up the new era of F5.5G commercial use.
  • Under this trend, Huawei proposes an F5.5G all-optical target network need to build an F5.5G all-optical target network that supports 3 network capabilities, and 4 network architecture.
  • Kim Jin said, "Huawei will continue to innovate based on the F5.5G all-optical target network, to help carriers seize development opportunities in the gigabit market and accelerate F5.5G commercial use, embracing the new wave of market prosperity."

Huawei Launches Three Innovative All-Optical Products to Open Up F5.5G Commercial Use

Retrieved on: 
Monday, February 26, 2024
GPON, Architecture, OptiX, PON, ETSI, TB, Cos, OTN, Huawei, OXC, K36, Packet loss, Ultra, OSN, Data-rate units, IEEE 802.11be

The three innovative products help operators build an F5.5G all-optical target network and accelerate development of 10G ultra broadband, together opening up the commercial use of F5.5G.

Key Points: 
  • The three innovative products help operators build an F5.5G all-optical target network and accelerate development of 10G ultra broadband, together opening up the commercial use of F5.5G.
  • Many countries and regions around the world have released 10G development plans and initiated the construction of 10Giga City.
  • To support the construction of the F5.5G all-optical target network with "1+3+4" architecture, Huawei has launched three innovative all-optical products.
  • Bob Chen, President of Huawei Optical Business Product Line, said, "2024 is the first year of F5.5G commercial use, and fixed networks will take a new leap forward.

Huawei Launches Three Innovative All-Optical Products to Open Up F5.5G Commercial Use

Retrieved on: 
Monday, February 26, 2024
GPON, Architecture, Multimedia, OptiX, PON, ETSI, TB, Cos, OTN, Huawei, OXC, K36, Packet loss, Ultra, OSN, Data-rate units, IEEE 802.11be, Mobile phone

The three innovative products help operators build an F5.5G all-optical target network and accelerate development of 10G ultra broadband, together opening up the commercial use of F5.5G.

Key Points: 
  • The three innovative products help operators build an F5.5G all-optical target network and accelerate development of 10G ultra broadband, together opening up the commercial use of F5.5G.
  • Many countries and regions around the world have released 10G development plans and initiated the construction of 10Giga City.
  • To support the construction of the F5.5G all-optical target network with "1+3+4" architecture, Huawei has launched three innovative all-optical products.
  • Second, the product implements physical isolation for services through an innovative architecture, ensuring E2E deterministic latency and jitter for premium services.

K36 Therapeutics Announces Presentation on KTX-1001 for Relapsed and Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Monday, December 4, 2023
Multiple myeloma, Therapy, ASH, Multiple Myeloma Research Foundation, Poster, Research, Exposition, Society, Relapse, Pharmaceutical industry, Patient, K36

CAMBRIDGE, Mass., Dec. 4, 2023 /PRNewswire/ -- K36 Therapeutics, Inc. ("K36"), a clinical-stage biotech company focused on developing its first-in-class MMSET inhibitor KTX-1001 for t(4;14) multiple myeloma, today announced that its abstract evaluating KTX-1001 in relapsed and refractory multiple myeloma has been accepted for presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held December 9-12, 2023, in San Diego, California, and online. Dr. Jesús G. Berdeja, the Director of Multiple Myeloma Research at Tennessee Oncology, will deliver the presentation as part of the Trials in Progress session.

Key Points: 
  • Dr. Jesús G. Berdeja, the Director of Multiple Myeloma Research at Tennessee Oncology, will deliver the presentation as part of the Trials in Progress session.
  • "I am delighted to be presenting the trial progress of KTX-1001 in high-risk subsets like translocation t(4;14)," stated Dr. Berdeja.
  • "There still remains an unmet need for new personalized oral therapies to treat multiple myeloma and novel precision therapeutics like KTX-1001 to address the challenges seen in high-risk patients with translocation t(4;14)."
  • Title: Trial in Progress: A Phase 1 Study of KTX-1001, an Oral, First-in-Class, Selective MMSET Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma

K36 Therapeutics Announces Appointment of Benjamin Winograd, MD, PhD, as Chief Medical Officer

Retrieved on: 
Wednesday, November 15, 2023
NDA, Multiple myeloma, Pharmacia, Pfizer, Bristol Myers Squibb, Senior, Therapy, Clinical trial, MUSC, Patient, Communication, Medicine, Clinical research, Prostate cancer, Schering-Plough, Kite Pharma, MD, Drug discovery, Allogeneic processed thymus tissue, BMS, Doctor of Philosophy, Health, Drug, BCMA, Lava, ChromeOS, Translational medicine, GSK plc, Medical imaging, Pharmaceutical industry, Management, Celgene, Temozolomide, K36

CAMBRIDGE, Mass., Nov. 15, 2023 /PRNewswire/ -- K36 Therapeutics, Inc. ("K36"), a clinical-stage biotech company focused on developing its first-in-class MMSET inhibitor KTX-1001 for t(4;14) multiple myeloma, today announced that Benjamin Winograd, MD, PhD, has been appointed Chief Medical Officer to lead the Medical and Clinical teams. Dr. Winograd joins K36 with a wealth of experience and a remarkable track record of bringing innovative medicines for hematological and solid tumor disease treatments to patients.

Key Points: 
  • Additional industry veterans recruited to strengthen clinical, translational medicine and preclinical teams
    CAMBRIDGE, Mass., Nov. 15, 2023 /PRNewswire/ -- K36 Therapeutics, Inc .
  • ("K36"), a clinical-stage biotech company focused on developing its first-in-class MMSET inhibitor KTX-1001 for t(4;14) multiple myeloma, today announced that Benjamin Winograd, MD, PhD, has been appointed Chief Medical Officer to lead the Medical and Clinical teams.
  • "Recruiting a leader with Dr. Winograd's expertise, reputation and track record of advancing transformative therapies validates the potential opportunity that KTX-1001 will deliver," said Terry Connolly, PhD, President and Chief Executive Officer of K36.
  • Most recently, Dr. Winograd was the Chief Medical Officer at Lava Therapeutics B.V. Dr. Winograd brings over 30 years of industry experience to K36, and will lead clinical development, translational medicine, regulatory affairs, and medical affairs.

K36 Therapeutics Announces FDA Clearance of Investigational New Drug Application and Formation of Clinical Advisory Board for Lead Program KTX-1001

Retrieved on: 
Tuesday, August 23, 2022
Associate Director of National Intelligence and Chief Information Officer, University, CA, Atlas Venture, Research, Cancer, Safety, Sarah Cannon Research Institute, IND, Regulation of tobacco by the U.S. Food and Drug Administration, Therapy, Associate, University of Toronto, Multiple myeloma, Achievement, Board, Food, University of San Francisco, Multiple Myeloma Research Foundation, Harvard University, Lysine, Hackensack University Medical Center, BCMA, SET, Atlas, Medical school, Center, MA, FDA, Biotechnology, Company, Capital, Efficiency, University of Salamanca, Review, Consultant, Patient, Pharmaceutical industry, Medicine, Medicine, DRS, K36

CAMBRIDGE, Mass., Aug. 23, 2022 /PRNewswire/ -- K36 Therapeutics, Inc. ("K36"), a privately held biotechnology company developing novel targeted therapies for the unmet medical needs of cancer patients, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) Application for the Company's lead program KTX-1001. KTX-1001 is an investigational small molecule methyltransferase inhibitor of multiple myeloma SET domain known as MMSET, a major regulator of chromatin structure and transcription in multiple myeloma. K36 plans to initiate a Phase 1 clinical trial in the second half of 2022 to establish the safety, tolerability and preliminary efficacy of KTX-1001 in patients with relapsed and refractory multiple myeloma, enriching for patients who have the genetic translocation t(4;14).

Key Points: 
  • KTX-1001 is an investigational small molecule methyltransferase inhibitor of multiple myeloma SET domain known as MMSET, a major regulator of chromatin structure and transcription in multiple myeloma.
  • K36 also announced the formation of its Clinical Advisory Board comprised of Drs.
  • The Phase 1 clinical trial is a single-arm, open-label study in subjects with relapsed and refractory multiple myeloma.
  • Our mission is to translate epigenetic modulation of oncogenic pathways into first-in-class small molecule therapeutics for the benefit of cancer patients worldwide.